Applied pharmacoeconomics: Modeling data from internal and external sources

American Journal of Health-System Pharmacy

Volumn 57, Issue 2, 2000, Pages 146-158

  Sanchez, Lisa A ^a   Lee, Jeffrey T ^b  

^a PE Applications Inc   (United States)

^b Advanced Health Outcomes   (United States)

Author keywords

Economics; Methodology; Models; Pharmacoeconomics

Indexed keywords

ANTIEMETIC AGENT;

COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE ORGANIZATION; MEDICAL DECISION MAKING; METHODOLOGY; MODEL; PRIORITY JOURNAL; REVIEW;

EID: 0034650595     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.2.146     Document Type: Review

References (27)

1. Sanchez LA. Some techniques for adapting pharmacoeconomics and outcomes research to pharmaceutical care. New Med. 1997; 1 (1):41-5.
2. Sanchez LA. Applied pharmacoeconomics: evaluation and use of pharmacoeconomic data from the literature. Am J Health-Syst Pharm. 1999; 56:1630-40.
3. Johnson NE. Data sources for economic outcomes analyses. In: Pharmacoeconomics and outcomes: applications for patient care. Module 2: assessment of economic outcomes. 1st ed. Kansas City, MO: American College of Clinical Pharmacy; 1996:69-76.
4. Milne RJ. Evaluation of the pharmacoeconomic literature. Pharmacoeconomics. 1994; 6:337-45.
5. Schecter CB. Decision analysis in formulary decision making. Pharmacoeconomics. 1993; 3:454-61.
6. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329:977-86.
7. Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med. 1997; 127:788-95.
8. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA. 1996; 276:1409-15.
9. Crane VS. Economic aspects of clinical decision-making: applications of clinical decision analysis. Am J Hosp Pharm. 1988; 45: 548-53.
10. Mutnick AH, Szymusiak-Mutnick B, Schumacher GE et al. Using decision analysis in the evaluation of drug therapy. Pharm Times. 1990; 56(11):59,61-4,66.
11. Barriere S. Formulary evaluation of second-generation cephamycin derivatives using decision analysis. Am J Hosp Pharm. 1991; 48: 2146-50.
12. 2-receptor antagonists for the formulary. Am J Hosp Pharm. 1990; 47:2002-6.
13. Harrison DL, Bootman JL, Cox ER. Cost-effectiveness of consultant pharmacists in managing drug-related morbidity and mortality at nursing facilities. Am J Health-Syst Pharm. 1998; 55:1588-94.
14. Paladino JA. Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis. Pharmacoeconomics. 1994; 5:505-12.
15. Kessler JM. Decision analysis in the formulary process. Am J Health-Syst Pharm. 1997; 54(suppl 1):S5-8.
16. Gaynan J. A cost-effectiveness model for analyzing two varicella vaccination strategies. Am J Health-Syst Pharm. 1998; 55(suppl 4): S4-8.
17. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm. 1997; 54:1185-90.
18. Garrelts JC, Horst WD, Silkey B et al. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy. 1994; 14:438-45.
19. Stergachis A. Overview of cost-consequence modeling in outcomes research. Pharmacotherapy. 1995; 15:40-2.
20. Mamdani MM, Weingarten CM, Stevenson JG. Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analysis. Pharmacotherapy. 1996; 16:1111-27.
21. Bjornson DC, Hiner WO, Potyk RP et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993; 50:1875-84.
22. Weinstein MC, Fineberg HV, Elstein AS et al. Clinical decision analysis. Philadelphia: Saunders; 1980:3-4.
23. Mauskopf J. Industry responsibility in interactive computer modeling. Med Care. 1996; 34(12, suppl):DS165-72.
24. Barr JT, Schumacher GE. Decision analysis and pharmacoeconomic evaluations. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney; 1996:150-77.
25. Keeler E. Decision trees and Markov models in cost-effectiveness research. In: Sloan FA, ed. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. Cambridge, England: Cambridge Univ. Press; 1995:185-205.
26. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13:322-38.
27. Naimark D, Krahn MD, Naglie G et al. Primer on medical decision analysis: part 5 - working with Markov processes. Med Decis Making. 1997; 17:152-9.